NZ Retatrutide Research
TRIUMPH-4 topline: 28.7% average weight loss at 68 weeks /// Triple agonist: GIP · GLP-1 · GCGR receptor activation /// New Zealand · Independent Research Resource /// TRIUMPH-4 reported · additional Phase 3 readouts expected in 2026 /// TRIUMPH-4 topline: 28.7% average weight loss at 68 weeks /// Triple agonist: GIP · GLP-1 · GCGR receptor activation /// New Zealand · Independent Research Resource ///
New Zealand’s Retatrutide Research Hub

The Next
Generation
Triple Agonist

Retatrutide simultaneously activates three metabolic receptors — GIP, GLP-1, and glucagon. In our full Retatrutide New Zealand guide, we break down how this triple agonist works, how it compares to existing GLP-1 drugs, and what current clinical data means for metabolic research in Aotearoa.

Read the Research Guide All Guides
28.7%
Mean Weight Loss
3×
Receptor Targets
Ph.3
Trial Stage
Phase 3 Topline

TRIUMPH-4: 28.7% Mean Weight Loss at 68 Weeks

Breaking down Lilly’s first successful Phase 3 readout in obesity with knee osteoarthritis — the numbers, the caveats, and what it means.

8 min read →
Mechanism

Triple Receptor Agonism: Why the GCGR Target Changes Everything

How glucagon receptor activation sets retatrutide apart from existing GLP-1 therapies.

6 min read →
NZ Access

Research-Use Peptides in New Zealand: A Practical Overview

Regulatory landscape, clinical context, and what New Zealand researchers need to understand.

5 min read →
2026 NZ Status Update

Retatrutide NZ status, trial data and Medsafe context.

Retatrutide remains investigational and is not an approved consumer medicine in New Zealand. NZReta maintains a 2026 status guide covering Medsafe context, clinical trial updates, fake-product risks and COA verification issues for New Zealand readers.

Read 2026 Status Guide →
Educational research resource · not medical advice
NZ Retatrutide Updates

Looking for Retatrutide in New Zealand?

Be notified when independently reviewed research sources, new batch testing, availability changes and important New Zealand regulatory updates are identified.

Research sources Batch testing NZ regulatory updates

No spam. Research, batch-testing, availability and New Zealand regulatory updates only. Unsubscribe anytime.

What Is Retatrutide

Three Targets.
One Molecule.

Where semaglutide and tirzepatide act on one or two receptors, retatrutide (LY3437943) is a once-weekly injectable peptide that simultaneously activates the GIP, GLP-1, and glucagon receptors — the first of its kind to reach late-stage clinical development.

The additional glucagon receptor component may drive significantly greater energy expenditure and fat oxidation compared to GLP-1 monotherapy, which researchers believe may explain the higher weight-loss figures seen in trials.

For a deeper comparison, see our retatrutide vs semaglutide comparison and our retatrutide vs tirzepatide analysis.

Research Context
Retatrutide is being studied as a next-generation triple agonist targeting GIP, GLP-1, and glucagon receptors.
  • GLPreceptor
    GLP-1 Receptor Agonism
    Reduces appetite and food intake. Slows gastric emptying. Shared mechanism with semaglutide and tirzepatide. Learn more in our GLP-1 mechanism guide.
  • GIPreceptor
    GIP Receptor Agonism
    Enhances insulin secretion and may influence GLP-1 receptor sensitivity. Also active in tirzepatide.
  • GCGreceptor
    Glucagon Receptor Agonism
    The third target — associated with increased energy expenditure, hepatic fat changes, and retatrutide’s distinct research profile.

Latest Research
& Analysis

All Guides
28.7%
Clinical Trial

Retatrutide New Zealand: Full Research Guide

A complete New Zealand-focused overview of retatrutide research, mechanisms, trial context, and where the compound sits within the wider GLP-1 landscape.

Guide Main hub Read Guide
vs
Comparison

Retatrutide vs Tirzepatide: Triple vs Dual Agonist

A direct comparison of retatrutide and tirzepatide, including receptor targets, weight-loss trial context, and mechanism differences.

Comparison 9 min Read
NZ
Comparison

Retatrutide vs Semaglutide: Next-Gen GLP-1 Research

How retatrutide compares with semaglutide across receptor activity, research outcomes, and clinical development.

Comparison 8 min Read
TRIUMPH-4 Key Data

The numbers
behind the latest TRIUMPH headline

28.7%
Mean body weight reduction at 68 weeks in the 12 mg retatrutide arm
Lilly TRIUMPH-4 topline
445
Participants randomized in the Phase 3 TRIUMPH-4 trial
NCT05931367
68wk
Co-primary endpoint timepoint used in the first successful Phase 3 readout
TRIUMPH-4 protocol
3×
Receptor targets: GIP · GLP-1 · Glucagon. First triple agonist in Phase 3
LY3437943 · Eli Lilly

This page includes TRIUMPH-4 topline Phase 3 context alongside earlier published Phase 2 research. This site presents research information only. Individual outcomes vary. Not medical advice.

Explore NZReta

Retatrutide research, comparisons, and GLP-1 science.

Start with the complete Retatrutide New Zealand guide, then explore how retatrutide compares with established metabolic research compounds including semaglutide and tirzepatide.

For a deeper mechanism breakdown, read our GLP-1 mechanism of action guide. You can also browse the full retatrutide guides library. For the latest regulatory and safety context, see our 2026 NZ status guide. For availability questions, see our where to buy retatrutide NZ guide, which covers availability, Medsafe context, COA checks and verification red flags.

Retatrutide New Zealand Guide

The core NZReta guide covering retatrutide research, mechanisms, and New Zealand context.

Read guide →

Retatrutide vs Semaglutide

Compare triple agonist retatrutide with GLP-1 semaglutide across mechanism and research data.

Compare →

Retatrutide vs Tirzepatide

Triple agonist vs dual agonist: a direct comparison for metabolic research context.

Compare →

GLP-1 Mechanism of Action

Understand GLP-1, GIP, and glucagon receptor activity behind next-generation metabolic research.

Learn mechanism →

All Retatrutide Guides

Browse the full NZReta research library and all published retatrutide-related guides.

View all guides →

Retatrutide NZ 2026 Status Guide

Current NZ status, Medsafe context, trial data, fake-product risks and COA verification issues in one trust-focused guide.

Read status guide →

Can You Buy Retatrutide in NZ?

A careful availability guide covering legal status, Medsafe context, COA verification, and red flags for New Zealand readers.

View availability guide →

Is My Retatrutide Fake?

Learn how to identify fake, underdosed, or unverified retatrutide using COAs, mass spec, batch matching, and supplier transparency checks.

Read guide →

Retatrutide Clinical Trials NZ

A full breakdown of retatrutide clinical trial data including Phase 2 studies, TRIUMPH, TRANSCEND, obesity outcomes, and future development.

View trials →
About NZReta

Maintained by NZReta Editorial Team

Last updated: June 2026
Editorial standards: How NZReta reviews content

NZReta publishes New Zealand-focused educational guides on retatrutide, clinical trial data, Medsafe status, peptide safety, fake-product risks and COA verification. The site is maintained to help readers understand the evidence, regulatory context and safety concerns around investigational compounds.

Retatrutide is not an approved consumer medicine in New Zealand. NZReta is an informational research resource and does not provide medical advice, prescribing advice, dosing guidance, sourcing advice or product recommendations.